Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751747 | 0.92 | PTPRB (0.73) | PTPRB | |
| Razuprotafib SCHEMBL17083766 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL468232 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083324 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083759 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083320 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL679459 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083334 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL468280 | 0.87 | PTPRB (1.00) | PTPRB | |
| Razuprotafib SCHEMBL17083328 | 0.87 | PTPRB (1.00) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115531352-B | Bioerodible ocular drug delivery inserts and methods of treatment | 视点制药公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-08-24 | — | — | US | disclosed |
| WO-2022133078-A1 | DOSAGE FORMS OF TIE-2 ACTIVATORS | EyePoint Pharmaceuticals, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | TIE1, TEK, KDR | PTPRB 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.